Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E30.76 EPS (ttm)2.74 Insider Own9.30% Shs Outstand2.62B Perf Week1.22%
Market Cap220.87B Forward P/E16.22 EPS next Y5.20 Insider Trans0.22% Shs Float2.48B Perf Month-2.37%
Income6.54B PEG4.65 EPS next Q1.24 Inst Own11.30% Short Float0.13% Perf Quarter12.97%
Sales49.23B P/S4.49 EPS this Y-2.80% Inst Trans0.09% Short Ratio1.49 Perf Half Y20.17%
Book/sh29.70 P/B2.84 EPS next Y9.67% ROA4.90% Target Price89.50 Perf Year0.93%
Cash/sh- P/C- EPS next 5Y6.61% ROE9.10% 52W Range66.93 - 86.90 Perf YTD15.72%
Dividend2.72 P/FCF70.52 EPS past 5Y-5.80% ROI7.30% 52W High-3.00% Beta0.75
Dividend %3.23% Quick Ratio0.80 Sales past 5Y-3.60% Gross Margin65.40% 52W Low25.94% ATR1.04
Employees119000 Current Ratio1.00 Sales Q/Q-1.50% Oper. Margin15.90% RSI (14)55.52 Volatility0.72% 0.84%
OptionableYes Debt/Eq0.44 EPS Q/Q11.10% Profit Margin13.30% Rel Volume0.47 Prev Close84.99
ShortableYes LT Debt/Eq0.33 EarningsJul 18 BMO Payout98.40% Avg Volume2.21M Price84.29
Recom2.30 SMA200.48% SMA502.42% SMA20011.17% Volume1,045,541 Change-0.82%
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Jul-24-17 04:50PM  Foreign Stock Roundup: ABB, Novartis Beat on Earnings Zacks
04:45PM  Biotechs Find Strength In Numbers In Treating Multiple Sclerosis Investor's Business Daily
02:35PM  Novartis in 2Q17: Performance of Innovative Medicines Market Realist
01:05PM  Foreign Exchange Impacts Novartiss Growth in 2Q17 Market Realist
11:15AM  Novartis: Heres What Impacted 2Q17 Earnings and Missed Estimates Market Realist
Jul-21-17 08:35AM  Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod Zacks
Jul-20-17 07:30PM  5 New Breast Cancer Treatments That Are Helping to Save Lives TheStreet.com
11:31AM  Novartis AG :NVS-US: Earnings Analysis: Q2, 2017 By the Numbers : July 20, 2017 Capital Cube
07:00AM  Earnings Review and Free Research Report: Novartis' EPS Grew 15% on Constant Currency Basis; Free Cash Flow Soared 28% Accesswire
Jul-19-17 01:30PM  FDA Panel Votes To Approve CTL019, Positive Implications for CYRX Zacks Small Cap Research
09:21AM  [$$] Novartis, Glaxo and Lilly Bigly Back New Biotech Barrons.com
07:33AM  Poor test results for Roche cloud growth prospects Reuters
Jul-18-17 04:47PM  Novartis beats 2Q profit forecasts Associated Press
04:16PM  These 2 Drug Giants In Buy Range Just Beat Earnings Views Investor's Business Daily
04:16PM  [$$] Novartis Looks Attractive; Eye-Care Unit Sees Upside Barrons.com
03:30PM  [$$] Novartis sales buoyed by recovery in eyecare unit Financial Times
01:48PM  [$$] Novartis Quarterly Net Income Beats Expectations The Wall Street Journal
01:30PM  Novartis AG (ADR) (NVS) Stock Pops on Solid Q2 Earnings InvestorPlace
10:37AM  Analyst Ratings and Recommendations for Novartis Post 2Q17 Market Realist
09:46AM  Novartis Tops Q2 Earnings, Sandoz Faces Pricing Pressure Zacks
09:08AM  Novartiss 2Q17 Estimates: Alcon, the Eye Care Business Market Realist
08:10AM  5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote Zacks
07:39AM  Novartiss 2Q17 Estimates: How Sandoz Might Perform Market Realist
06:51AM  5 Things You Must Know Before the Market Opens Tuesday TheStreet.com
04:20AM  European Stocks Drift Lower; Dollar Slumps Further After Healthcare Bill Collapse TheStreet.com
03:32AM  Novartis Tops Q2 Earnings Estimate, Boosts Alcon Full Year Sales Guidance TheStreet.com
03:27AM  Novartis sees Alcon recovery opening door to spin-off IPO Reuters
03:18AM  Novartis' CEO Says Getting Momentum Back in Alcon Unit Bloomberg Video
03:11AM  Novartis net profit grows 10 percent in Q2, but sales dip Associated Press
01:23AM  Novartis Points to Early Signs of Rebound at Alcon Eye-Care Unit Bloomberg
01:07AM  Our M&A strategy focused on bolt-on acquisitions: Novarti... CNBC Videos
01:07AM  Novartis CEO: About to enter next growth phase CNBC Videos
01:00AM  Novartis Second Quarter Core EPS Beats Estimates Bloomberg
12:58AM  Continuing to innovate, launch new drugs in US: Novartis ... CNBC Videos
Jul-17-17 01:35PM  Novartiss 2Q17 Estimates: Innovative Medicines Segment Market Realist
12:05PM  Analysts Expect Novartiss Revenues to Fall in 2Q17 Market Realist
11:26AM  How Bayer Is Creating Value through Innovation Market Realist
11:26AM  How Bristol-Meyers Squibb Has Benefited from Intangible Assets Market Realist
10:27AM  Novartiss 2Q17 Earnings: Analyst Estimates Market Realist
Jul-16-17 03:03PM  Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter Motley Fool
Jul-15-17 12:03PM  Why You're Smart to Buy Vertex Pharmaceuticals Stock Motley Fool
Jul-14-17 08:18AM  Can Novartis (NVS) Spring a Surprise This Earnings Season? Zacks
07:44AM  Novartis stocks drug cabinet with "Big-3" arthritis blockbusters Reuters
07:30AM  [$$] Gormley's Take: Racing Against Time to Defeat Cancer The Wall Street Journal
07:28AM  Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co. Zacks
Jul-13-17 11:47PM  Abbott, Novartis Show Promise Amid Healthcare Decline, Tiffany Lands Much Needed Boost -ICYMI Thurs. TheStreet.com
07:31PM  A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared Motley Fool
04:49PM  Novartis CAR-T Therapy Drug Recommended by FDA Panel Zacks
04:49PM  [$$] 3 Drug Stocks That Can Ride Novartis' Coattails Barrons.com
04:24PM  How Novartis' FDA Win In Cancer Also Could Be A Boon For Its Rivals Investor's Business Daily
02:00PM  CAR-Ts Clear One Roadblock But Face Many More Bloomberg
10:30AM  Is Juno Therapeutics Stock Still a Strong Buy? Motley Fool
09:48AM  Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others TheStreet.com
09:47AM  Novartis FDA Panel Approval: 'Pharma Innovation At Its Best' Barrons.com
06:49AM  FDA panel backs Novartis cancer drug CNBC Videos
06:00AM  T-cell cancer therapy holds promise, longer-term results await Reuters
04:05AM  Novartis gets FDA panel approval for leukemia treatment CNBC Videos
12:21AM  [$$] FDA Panel Votes Unanimously to Support Leukemia Gene-Therapy Treatment The Wall Street Journal
12:20AM  [$$] The Price Dilemma Over a $16,000 Drug The Wall Street Journal
Jul-12-17 06:01PM  A Cancer Breakthrough Near FDA Approval Has a Costly Side Effect Bloomberg
05:46PM  Novartis gets FDA panel recommendation for leukemia drug approval MarketWatch
05:44PM  [$$] The Price Dilemma Over a $16,000 Drug The Wall Street Journal
05:28PM  A cancer treatment that one expert called the 'most exciting thing Ive seen in my lifetime' just got closer to approval Business Insider
05:08PM  Novartis Grabs Key FDA Panel Approval Of Experimental Cancer Drug Investor's Business Daily
04:49PM  FDA panel backs Novartis' pioneering new cancer gene therapy Reuters
04:24PM  [$$] FDA Panel Votes to Support Leukemia Gene-Therapy Treatment The Wall Street Journal
04:21PM  [$$] Novartis cancer drug moves step closer to approval Financial Times
03:50PM  Novartis Secures FDA Panel's Approval for Cutting Edge Cancer Drug TheStreet.com
03:28PM  A revolutionary experimental cancer treatment just got one step closer to approval Business Insider
09:50AM  Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday TheStreet.com
Jul-11-17 02:19PM  FDA Decision on Novartis Gene Therapy Drug Could Benefit Kite Pharma TheStreet.com
01:20PM  FDA Moves On Novartis Gene Therapy May Be Good For Kite Pharma Barrons.com
09:14AM  Novartis readies for FDA review of $1 bln CAR-T child cancer hope Reuters
09:04AM  Heres how much the 10 largest pharmaceutical companies spend on R&D Business Insider
Jul-10-17 04:44PM  The 10 largest pharmaceutical companies in the world Business Insider
11:12AM  Novartis' Cosentyx Superior to Stelara in Psoriasis Study Zacks
09:25AM  FDA panel to focus on safety of Novartis gene therapy drug Reuters
08:33AM  FDA panel to focus on safety of Novartis gene therapy drug Reuters
Jul-07-17 03:51PM  Novartis Stock in 2Q17: How Has It Performed? Market Realist
09:09AM  How BMYs Opdivo Is Expected to Perform in 2017 Market Realist
08:50AM  Why Conatus Pharma Wins With Newest Licensing Agreement 24/7 Wall St.
03:00AM  Sophies Choice for Oncologists: Who Gets New Life-Saving Drug Bloomberg
Jul-06-17 04:25PM  Novartis Faces Key FDA Panel On Cancer Drug; Why Kite Could Be The Winner Investor's Business Daily
03:29AM  Oxford BioMedica wins big contract for Novartis cell therapy Reuters
12:06AM  Lung, Liver and Stomach Cancers Kill a Million Chinese a Year; Big Pharma Responds The Wall Street Journal
Jul-05-17 04:14PM  Tesla's Stock Is Only Worth This Much: Goldman Investor's Business Daily
04:12PM  These 6 Biotech, Drug Plays Are In Buy Range: Investing Action Plan Investor's Business Daily
09:54AM  These 6 Biotech, Drug Plays Are In Buy Range: Investing Action Plan Investor's Business Daily
07:30AM  [$$] Biotechs Race to Unleash Cellular Cancer Therapies The Wall Street Journal
07:00AM  Why Big Pharma Is Targeting China's Deadliest Diseases The Wall Street Journal
Jul-04-17 10:37AM  Johnson & Johnsons Pharmaceuticals Business in 1Q17 Market Realist
07:53AM  Incyte & Lilly's Olumiant Gets Marketing Approval in Japan Zacks
12:00AM  Why Big Pharma Is Struggling to Profit From the Obesity Epidemic Bloomberg
Jul-03-17 09:30AM  The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva Zacks
Jun-30-17 01:10PM  The Cure For Cancer? Look At Your Blood Investor's Business Daily
10:40AM  Bluebird Bio: Too Much Good News? Barrons.com
08:15AM  Pharma Stock Roundup: Sanofi RA Drug Gets EU Nod, Merck CETP Inhibitor Surprises Zacks
05:00AM  Popular Cancer Pill Goes Generic, Yet Patients' Costs Stay High Bloomberg
Jun-29-17 09:54AM  Novartis Gets EC Nod for Lung Cancer Drug's Label Expansion Zacks
09:30AM  Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca Zacks
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segments also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies. The Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The Alcon segment offers eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses for use in surgical procedures to treat cataracts, vitreoretinal conditions, glaucoma, and refractive errors; and contact lenses and lens care products. The company has collaboration and licensing agreements with Xencor for the development of bispecific antibodies for treating cancer; and Surface Oncology to access four pre-clinical programs in immuno-oncology. It also has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and Caribou Biosciences for the development of drug discovery tools. In addition, the company has a clinical research collaboration with Bristol-Myers Squibb Company to investigate Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in combination with Mekinist as a treatment option for metastatic colorectal cancer. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerJul 05Buy15.00266,6674,000,0052,544,182Jul 05 06:05 PM
Novartis Bioventures Ltd10% OwnerJun 19Sale22.023,22070,8992,251,457Jun 20 04:41 PM
Novartis Bioventures Ltd10% OwnerJun 16Sale21.2453,2001,130,2072,254,677Jun 20 04:41 PM
Novartis Bioventures Ltd10% OwnerJun 08Sale22.0070015,4002,307,877Jun 12 04:12 PM
Novartis Bioventures Ltd10% OwnerJun 07Sale22.114,840106,9992,308,577Jun 08 04:33 PM
Novartis Bioventures Ltd10% OwnerJun 06Sale22.987,274167,1612,313,417Jun 08 04:33 PM
Novartis Bioventures Ltd10% OwnerJun 05Sale23.114,780110,4882,320,691Jun 06 04:27 PM
Novartis Bioventures Ltd10% OwnerJun 02Sale23.4714,867348,9492,325,471Jun 06 04:27 PM
Novartis Bioventures Ltd10% OwnerJun 01Sale23.8910,722256,1762,340,338Jun 02 04:25 PM
Novartis Bioventures Ltd10% OwnerMay 31Sale23.9435,539850,8962,351,060Jun 02 04:25 PM
Novartis Bioventures Ltd10% OwnerMay 26Sale25.145,300133,2672,386,599May 30 04:29 PM
Novartis Bioventures Ltd10% OwnerMay 25Sale25.00531,3252,391,899May 30 04:29 PM
Novartis Bioventures Ltd10% OwnerMay 24Sale25.0117,451436,3642,391,952May 25 04:57 PM
Novartis Bioventures Ltd10% OwnerMay 18Sale25.509,019229,9642,409,403May 22 06:50 PM
Novartis Bioventures Ltd10% OwnerMay 17Sale25.5122,534574,9012,418,422May 18 04:36 PM
Novartis Bioventures Ltd10% OwnerMay 16Sale26.3320,081528,7252,440,956May 18 04:36 PM
Novartis Bioventures Ltd10% OwnerMar 15Buy5.00560,0002,800,0005,805,550Mar 17 08:36 PM
Novartis Bioventures Ltd10% OwnerMar 01Sale20.917,778162,6582,461,037May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 28Sale20.867,847163,6702,468,815May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 27Sale20.9657,8441,212,3062,476,662May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 24Sale20.935,398113,0002,534,506May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 23Sale21.044,999105,1602,539,904May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 22Sale21.8674916,3702,544,903May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerOct 31Buy13.0084,6151,099,9952,545,652Oct 31 04:50 PM
Novartis Bioventures Ltd10% OwnerOct 31Sale13.003394,40762,575Oct 31 04:50 PM